BMY - Halozyme Therapeutics: The Story Brightens
2024-06-07 10:32:06 ET
Summary
- Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher.
- Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stock, and the shares are still reasonably valued.
- An updated analysis around this mid-cap biopharma name follows in the paragraphs below.
Today, we are following up on mid-cap biopharma concern Halozyme Therapeutics, Inc. ( HALO ) as the company issued an important FY2024 guidance update on Thursday. The company also provided updated 5-Year guidance that was triggered by a new European patent for ENHANZE®. The improved guidance resulted in a just over 12% rise in the shares in trading yesterday. This added to the rally in the equity since Halozyme reported quarterly results one month ago....
Halozyme Therapeutics: The Story Brightens